Final Results of a Phase II Trial of Preoperative TAC (Docetaxel/Doxorubicin/Cyclophosphamide) in Stage III Breast Cancer

Based on the pCR rate seen in this trial, docetaxel given concomitantly with AC (doxorubicin/cyclophosphamide) for 4 cycles does not appear to be superior to 4 cycles of AC as preoperative treatment for stage III breast cancer. Based on other trials, longer durations of therapy and/or sequencing of AC and docetaxel may result in a higher pCR rate.